AIM: To identify characteristics of suboptimally controlled patients with type 2 diabetes (T2DM) on basal insulin treatment who may benefit from intensive titration or further intensification of treatment. METHODS: A post hoc analysis of SOLVE: a 24-week, international, observational study conducted in 17,374 patients with T2DM inadequately controlled on oral antidiabetic drugs (OADs) started on once-daily insulin detemir. Patients were divided into two groups based on whether they achieved HbA1c10years: 1.44 [1.17;1.77]; p2 OADs: 1.38 [1.14;1.66]; p=0.0003). Overall reporting of hypoglycemia was low; fewer patients with HbA1c⩾7.0% (⩾53.0mmol/mol) reported hypoglycemic events compared with patients with HbA1c<7.0% (9.8% vs. 12.5%, respectiv...
AbstractAimsTo investigate treatment patterns and achievement of glycemic targets in patients with t...
Introduction National Diabetes Registry showed that insulin used among type 2 diabetic (T2DM) has in...
Aims. Basal insulin plus oral hypoglycemic agents (OHAs) has not been investigated for early intensi...
Aim: To identify characteristics of suboptimally controlled patients with type 2 diabetes (T2DM) on ...
AIMS: The aim of this analysis was to assess the efficacy and safety of intensifying insulin therapy...
OBJECTIVESTo evaluate the characteristics of patients with type 2 diabetes newly treated with basal ...
Objective: To evaluate hospitalized type 2 diabetes mellitus (T2DM) patients with dissimilar insulin...
AIMS: To describe in a real-world setting the achievement of physician-selected individualized HbA1c...
BACKGROUND: When target glycated hemoglobin (HbA1C) levels are not reached, basal insulin therapy sh...
AIMS: To evaluate factors associated with reaching or not reaching target glycated haemoglobin (HbA1...
Introduction: Improving management practices and clinical outcomes in type 2 diabetes (IMPACT), was ...
This analysis investigated factors associated with the decrease in HbA1c in patients receiving conti...
Background: The aim of the present study was to identify demographic and treatment factors that were...
Objective: For many patients with type 2 diabetes, oral antidiabetic agents (OADs) do not provide op...
OBJECTIVE: For many patients with type 2 diabetes, oral antidiabetic agents (OADs) do not provide op...
AbstractAimsTo investigate treatment patterns and achievement of glycemic targets in patients with t...
Introduction National Diabetes Registry showed that insulin used among type 2 diabetic (T2DM) has in...
Aims. Basal insulin plus oral hypoglycemic agents (OHAs) has not been investigated for early intensi...
Aim: To identify characteristics of suboptimally controlled patients with type 2 diabetes (T2DM) on ...
AIMS: The aim of this analysis was to assess the efficacy and safety of intensifying insulin therapy...
OBJECTIVESTo evaluate the characteristics of patients with type 2 diabetes newly treated with basal ...
Objective: To evaluate hospitalized type 2 diabetes mellitus (T2DM) patients with dissimilar insulin...
AIMS: To describe in a real-world setting the achievement of physician-selected individualized HbA1c...
BACKGROUND: When target glycated hemoglobin (HbA1C) levels are not reached, basal insulin therapy sh...
AIMS: To evaluate factors associated with reaching or not reaching target glycated haemoglobin (HbA1...
Introduction: Improving management practices and clinical outcomes in type 2 diabetes (IMPACT), was ...
This analysis investigated factors associated with the decrease in HbA1c in patients receiving conti...
Background: The aim of the present study was to identify demographic and treatment factors that were...
Objective: For many patients with type 2 diabetes, oral antidiabetic agents (OADs) do not provide op...
OBJECTIVE: For many patients with type 2 diabetes, oral antidiabetic agents (OADs) do not provide op...
AbstractAimsTo investigate treatment patterns and achievement of glycemic targets in patients with t...
Introduction National Diabetes Registry showed that insulin used among type 2 diabetic (T2DM) has in...
Aims. Basal insulin plus oral hypoglycemic agents (OHAs) has not been investigated for early intensi...